ANNALS OF ONCOLOGY
ANNALS OF ONCOLOGY(英文缩写 ANN ONCOL),ISSN 0923-7534,eISSN 1569-8041 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
指标来源：jcr_cas_ifqb
期刊简介
暂无简介。
历年影响因子趋势
| 年份 | 影响因子 | JCR 分区 |
|---|---|---|
| - | Q1 | |
| - | Q1 | |
| - | Q1 | |
| - | Q1 | |
| - | Q1 |
ANNALS OF ONCOLOGY 最新收录文献
-
Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer.
Treatment outcomes for patients with metastatic non-small-cell lung cancer (NSCLC) are poor with chemotherapy. In recent years, novel agents that target specific, aberrant molecular pathways in NSCLC …
-
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that targets both angiogenic pathways (i.e., vascular endothelial growth factor receptor and platelet-derived growth factor recepto…
-
Treatment options in renal cell carcinoma: past, present and future.
Cytokine therapies have been the standard of care in metastatic renal cell carcinoma (RCC). However, these agents only provide clinical benefit to a small subset of patients and are associated with si…
-
Advances in the treatment of gastrointestinal stromal tumours.
Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatment for unresectable or metastatic gastrointestinal stromal tumour (GIST), improving survival time a…
-
Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib.
Conventional methods to assess the clinical activity of new agents that target specific biological pathways involved in tumour pathology may not provide correlation with clinically relevant outcomes s…
-
Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'.
Although single-target agents have been shown to improve patient outcomes in certain tumour types, drug resistance often occurs due to salvage pathways that compensate for the inhibited signalling pat…
-
Occasional FDG PET recognition of in situ breast cancer.
-
Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.
-
The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry.
-
Small tumor of the medial breast presenting with a contralateral lymph node involvement detected on positron emission tomography scan.